Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non–Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial

PURPOSE: Trastuzumab deruxtecan (T-DXd) 5.4 and 6.4 mg/kg showed robust antitumor activity in multiple cancer indications; however, T-DXd 5.4 mg/kg has not been evaluated in patients with previously treated human epidermal growth factor receptor 2–mutant (HER2m; defined as single-nucleotide variants...

Descripción completa

Detalles Bibliográficos
Autores principales: Goto, Koichi, Goto, Yasushi, Kubo, Toshio, Ninomiya, Kiichiro, Kim, Sang-We, Planchard, David, Ahn, Myung-Ju, Smit, Egbert F., de Langen, Adrianus Johannes, Pérol, Maurice, Pons-Tostivint, Elvire, Novello, Silvia, Hayashi, Hidetoshi, Shimizu, Junichi, Kim, Dong-Wan, Kuo, Chih-Hsi, Yang, James Chih-Hsin, Pereira, Kaline, Cheng, Fu-Chih, Taguchi, Ayumi, Cheng, Yingkai, Feng, Wenqin, Tsuchihashi, Zenta, Jänne, Pasi A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2023
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10617843/
https://www.ncbi.nlm.nih.gov/pubmed/37694347
http://dx.doi.org/10.1200/JCO.23.01361

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10617843/
https://www.ncbi.nlm.nih.gov/pubmed/37694347
http://dx.doi.org/10.1200/JCO.23.01361

Ejemplares similares